BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//6.6.4.4//EN
TZID:Asia/Jerusalem
X-WR-TIMEZONE:Asia/Jerusalem
BEGIN:VEVENT
UID:1032@biotech.technion.ac.il
DTSTART;TZID=Asia/Jerusalem:20171122T160000
DTEND;TZID=Asia/Jerusalem:20220202T155700
DTSTAMP:20220512T124724Z
URL:https://biotech.technion.ac.il/events/single-molecule-arrays-for-advan
 ced-diagnostics-ultrasensitive-detection-of-anti-sars-cov-2-antibodies-and
 -viral-antigens-for-clinical-applications/
SUMMARY:Single Molecule Arrays for advanced diagnostics: ultrasensitive det
 ection of anti-SARS-CoV-2 antibodies and viral antigens for clinical appli
 cations
DESCRIPTION:Molecular diagnostics have the potential to revolutionize our a
 bility to diagnose\, monitor and treat a variety of diseases. However\, de
 tecting circulating biomarkers has proven to be challenging due to the low
  concentrations of many biomarkers. Furthermore\, other factors including 
 sample heterogeneity\, low sample volume\, and cross-reactivity between di
 fferent markers complicate biomarkers detection. Consequentially\, there i
 s a need for improved biomarker detection methods.  The emergence of sing
 le-molecule techniques opens new opportunities to overcome these challenge
 s. Counting individual molecules enables the detection of biomarkers at lo
 w quantities. Additionally\, single-molecule technologies are particularly
  relevant to the analysis of heterogeneous samples\, and can allow for bio
 markers detection with a wide dynamic range. The Walt lab previously devel
 oped an ultra-sensitive assay known as Single Molecule Arrays (Simoa) by i
 solating single molecules into femtoliter-sized compartments using microfl
 uidics\, and detecting them optically. The Simoa technology enables biomar
 kers to be measured at concentrations a thousand times lower than current 
 molecular diagnostic methods\, providing a more accurate approach for diag
 nosing certain forms of cancer\, infectious diseases and neurodegenerative
  disorders.  Recently\, the COVID-19 pandemic has led to an urgent need f
 or robust diagnostic assays. To address this need\, we developed ultra-sen
 sitive Simoa based methods for the detection of anti-SARS-CoV-2 antibodies
  and viral antigens\, and an assay for the quantification of antibody neut
 ralization capacity. We used these new assays to study important clinical 
 problems in collaboration with clinicians in Brigham and Women's Hospital 
 and Massachusetts General Hospital. For example\, we studied the mechanism
  of Multisystem Inflammatory Syndrome in Children (MIS-C). Our new finding
 s on MIS-C pathogenesis provide novel targets for treating and preventing 
 MIS-C\, which are urgently needed for this increasingly common\, severe CO
 VID-19-related disease in children. The past year has expedited the use of
  Simoa in the clinic\, and we are now excited about further developing and
  applying single molecule detection methods for numerous clinical applicat
 ions.\n\n&nbsp\;\n\nAbstract
CATEGORIES:סמינרים
END:VEVENT
BEGIN:VTIMEZONE
TZID:Asia/Jerusalem
X-LIC-LOCATION:Asia/Jerusalem
BEGIN:STANDARD
DTSTART:20171029T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20180323T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20181028T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20190329T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20191027T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20200327T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20201025T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20210326T030000
TZOFFSETFROM:+0200
TZOFFSETTO:+0300
TZNAME:IDT
END:DAYLIGHT
BEGIN:STANDARD
DTSTART:20211031T010000
TZOFFSETFROM:+0300
TZOFFSETTO:+0200
TZNAME:IST
END:STANDARD
END:VTIMEZONE
END:VCALENDAR